Viking Therapeutics, Inc. - 8-K Filing
Viking Therapeutics reports Q3 2026 financial results and announces initiation of SUNRISE Phase 3 oral VK2735 trials. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)
Tickers: $VKTX
Read the full article at SEC EDGAR
Part of the story Crescent Capital BDC Reports Q3 2026 Earnings with Increased Net Investment Income (48 articles)